Pittsburgh, PA -- (SBWIRE) -- 03/10/2011 -- ChemImage Corporation was recently awarded a $17-million contract by the U.S. Army Space & Missile Defense Command for the implementation of its real-time sensor technology that will be used in the field to detect explosive threats.

The work to be performed in this contract will include the fabrication and delivery of multiple sensors to the U.S. Army, as well as product testing, soldier training and field support. General Dynamics Armament and Technical Products has teamed with ChemImage to support this effort.

"This is a landmark event for our company," said Patrick Treado, Ph.D., Founder & Chief Technology Officer at ChemImage. "We're honored that ChemImage technology will be used to help keep U.S. soldiers and our country safe."

In addition to this contract award, ChemImage was one of 25 companies recently identified as a participant of the U.S. Army Small Business Innovation Research (SBIR) 2011 Commercialization Pilot Program (CPP) to help transition similar technology from research and development to commercial use.

For more information on ChemImage's threat detection capabilities, visit http://Ez.com/threatdetection.

About ChemImage
ChemImage Corporation, a leader in hyperspectral (i.e. chemical) imaging technology, provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art hyperspectral imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems. ChemImage's headquarters are located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 01/06/2011 -- Results from a blinded hyperspectral imaging (HSI) study examining ink from 44 black ballpoint pens, totaling 500 ink samples in all, will be presented, Friday, Feb. 25 from 11:30-11:50 a.m. at the American Academy of Forensic Sciences (AAFS) 63rd Annual Scientific Meeting at the Hyatt Regency Hotel in Chicago.

Conducted by ChemImage Corporation, the study will look at different combinations of pen pair samples to better ascertain HSI's ability to detect, discriminate and provide sample-to-sample and sample-to-background contrast. In addition to discussing overall results, the presentation will address any potential sources of error, as well as provide a general comparison of HSI performance to other ink discrimination techniques.

The pen pairs utilized in the ChemImage study originated from research results published in the July 2007 edition of the Journal of Forensic Sciences, where video spectral analysis and lab color mode were used to analyze 990 black ballpoint pen pair ink samples.

In addition to the presentation, ChemImage will be exhibiting at booth #912 at the conference, where it will be giving away an iPad.

For more information on the company's forensic applications, visit: http://www.chemimage.com/forensics/.

About ChemImage
ChemImage Corporation, a leader in hyperspectral imaging technology (i.e., molecular chemical imaging), provides instrumentation, software and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters are located in Pittsburgh, Pa., where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 12/22/2010 -- ChemImage Corporation is one of 25 companies recently identified to participate in the U.S. Army Small Business Innovation Research (SBIR) 2011 Commercialization Pilot Program (CPP) for its real-time chemometrics and sensor fusion (RTCSF) technology.

Developed under a Phase II SBIR managed by the Army Research Office (ARO), ChemImage's RTCSF technology will enable the real-time detection of chemical, biological and explosive threats. In 2011, the company will receive program support to accelerate its transition from research and development to commercial use.

"After rigorous analysis by U.S. Army SBIR, we're pleased that the work being performed under the RTCSF project addresses high priority Army needs," said Patrick Treado, PhD., Founder & Chief Technology Officer at ChemImage. "The support we'll receive from the CPP will assist us in fielding this innovative ChemImage technology for use by Soldier Operators."

Companies identified for CPP participation most strongly exemplify the program's mission goals of addressing high priority Army needs, exhibiting the potential for accelerated transition and offering high commercialization potential. Program assistance includes: business and transition plan development, potential investment needs planning and justification, and facilitation of meetings with potential private and/or government customers.

The U.S. Army established the SBIR CPP in 2007 in response to the 2006 National Defense Authorization Act, with the purpose of increasing SBIR technology transition and commercialization success.

For more information on ChemImage's threat detection capabilities, visit http://www.chemimage.com/threat.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 12/10/2010 -- ChemImage Corporation recently reported results from a hyperspectral imaging (HSI) study that displayed a 42.8% overall improvement in characterization of untreated latent fingerprints in comparison to previous HSI image processing methods.

Improved data collection and image processing techniques were used to examine aged and recently deposited latent fingerprints on various surfaces that typically prove to be more difficult for forensic scientists, including white lined paper, white printer paper, a white business card, black tape and aluminum foil. The result yielded fingerprint images with enhanced detail between the ridge and the substrate without the use of chemical agents.

"While the chemical development of fingerprints will always play an important role in forensic analyses, there are certain instances, such as prints deposited on valuable or old surfaces or those requiring DNA extraction, where it can be detrimental to use such methods," said John Belechak, Chief Operating Officer and Forensic Science Director at ChemImage. "We are encouraged by these findings because they bring our innovative hyperspectral imaging technology one step closer to being a validated alternative."

HSI takes conventional methods to the next level by adding a spectroscopic basis for sample analysis, enabling the identification and enhancement of contrast between chemically different materials.

Complete results from this study were published in the November/December issue of the Journal of Forensic Identification, a scientific publication of the International Association of Identification, in an article titled "Improved Methods of Visible Hyperspectral Imaging Provide Enhanced Visualization of Untreated Latent Fingerprints."

In addition to latent fingerprints, ChemImage is also researching the application of HSI for bloodstain analysis and questioned document examination (including security documents). For more information on the company's forensic applications, visit: http://www.chemimage.com/forensics/.

About ChemImage
ChemImage Corporation, a leader in hyperspectral imaging technology (i.e., molecular chemical imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters are located in Pittsburgh, Pa., where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 09/29/2010 -- ChemImage Corporation will be exhibiting its Hyperspectral Imaging (HSI) instrumentation at the Midwestern Association of Forensic Scientists (MAFS) 39th Annual Meeting, Oct. 4-8 at the Kansas City Marriott Downtown, Kansas City, Mo.

A proud supporter of the meeting, ChemImage will have its HSI Examiner™ 100 QD available at booth number 12 for live demonstration. Designed specifically for questioned document examination, the HSI Examiner combines spectroscopy with digital imaging to show small spectral variances of chemically different materials. The Examiner's advanced hyperspectral resolution, paired with its 2x faster image acquisition speed than video spectral analysis-based technology, make it well-suited for forensic casework.

Chocked full of educational workshops, sessions and events, the 2010 MAFS meeting will cover a wide range of topics, including crime scenes, latent prints, DNA and bloodstain pattern analysis.

For more information on ChemImage's activities at the MAFS Annual Meeting, visit http://www.chemimage.com/mafs.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (i.e., Molecular Chemical Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 08/24/2010 -- ChemImage Corporation recently reached an agreement with Light Ace HK LTD, a China-based distributor of laboratory equipment, instrumentation and services, to offer the Falcon II Wide-Field Raman Chemical Imaging System and select analytical contract services in China.

"This agreement affirms the value chemical imaging can bring to the international marketplace," said Jim McGlone, president at ChemImage. "We look forward to working with Light Ace to develop a stronger presence in China."

The only system of its kind optimized for both chemical imaging, and spectroscopy, the Falcon II identifies material morphology, composition, structure, size and concentration of constituents in a sample. Falcon II services now offered through Light Ace include ingredient-specific particle sizing, polymorph analysis, content uniformity and controlled release characterization applications.

"We're pleased to be adding this instrument to our innovative line of product offerings," said Jason Wu, general manager of Light Ace HK Limited. "Due to its versatility and superior discrimination ability, we're confident that our target market will be receptive to the Falcon II and its service offerings."

Raman chemical imaging (RCI), a technique that combines digital imaging with spectroscopy, is used to obtain spectrally and spatially resolved images of a sample. ChemImage RCI products utilize liquid-crystal tunable filter technology, allowing for more precise chemical identification and size measurement.

More information on Light Ace HK LTD can be found at its Web site: www.lightace.com.cn/. Visit www.chemimage.com for additional details on ChemImage.

China-based inquiries on the Falcon II and its services may be directed to Jason Wu, general manager of Light Ace HK Limited, by phone at 86-10-82168066 or email at jasonwu@lightace.com.cn.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

About Light Ace
Light Ace, a private-holding Company whose business is based in China mainland, was and still is a major player in laboratory equipment and instrumentation since the beginning of 1980s.

Light Ace has 26 years experience of sales and service in China since 1984, especially in the domain of optical instrumentation, and has built up a strong sales and support team to provide superior quality products and extensive knowledge to end-users. Today, Light Ace's services are involved in lab analytical and biological chemistry, field analytical chemistry, process chemical analysis, lab equipment, and turnkey general contract.

Light Ace is headquartered in Beijing and has branch and representative offices in Shanghai, Guangzhou, and Chengdu for covering the business throughout the China mainland.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 08/18/2010 -- ChemImage Corporation will be presenting research results on a new inkjet printer discrimination technique involving hyperspectral imaging (HSI) at the 6th EDEWG Conference, a meeting of the European Document Experts Working Group, in Dubrovnik, Croatia from Sept. 21-24.

A part of the European Network of Forensic Science Institutes (ENFSI), the European Document Experts Working Group supports ENFSI's forensic document examination objectives. Held every two years, the 6th EDEWG Conference will offer workshops, scientific sessions and posters illustrating new developments in toner and ink examination.

The presentation, titled "Discrimination of Inkjet Printer Ink," will examine HSI's ability to link documents printed from different inkjet printers to a common manufacturer or ink formulation. Initial research found that the cyan, yellow and magenta components of each type of printer brand have their own unique spectroscopic responses.

HSI takes conventional photography and imaging methods to the next level by adding a spectroscopic basis for sample analysis. The result enables the identification and enhancement of contrast between chemically different materials.

In addition to the presentation, ChemImage will also be exhibiting throughout the conference's duration.

For more information about the company's activities at the 6th EDEWG Conference, visit http://www.chemimage.com/EDEWG.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 08/12/2010 -- ChemImage Corporation will be instructing a workshop on the basic theories and methods associated with hyperspectral imaging (HSI) on Friday, Sept. 10 at the 20th International Symposium on the Forensic Sciences, a biennial meeting of the Australian New Zealand Forensic Science Society in Sydney, Australia.

The three-hour workshop will focus on several of HSI's forensic applications, including questioned document examination, fingerprint imaging on complex backgrounds and bloodstain imaging on dark backgrounds. This session will also give attendees the opportunity to get some hands-on experience using the ChemImage HSI ExaminerTM 100 QD, the first commercially available HSI instrument for questioned document examination.

Hyperspectral imaging takes conventional photography and imaging methods to the next level by adding a spectroscopic basis for sample analysis. The result enables the identification and enhancement of contrast between chemically different materials.

In addition to the session, ChemImage will also be exhibiting at booth number 31 throughout the symposium's Sept. 4-9 duration.

For more information about the company's activities at the International Symposium on the Forensic Sciences, visit http://www.chemimage.com/ANZFSS.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 08/11/2010 -- A study conducted by scientists at ChemImage Corporation, in partnership with a well-known U.S. medical research and treatment center, revealed that Raman Molecular Imaging (RMI), a type of hyperspectral imaging, has potential in predicting the progression of prostate cancer.

Blinded samples from 38 patients with Gleason score 7 prostate cancer were evaluated using RMI, an emerging technology that combines digital imaging and molecular spectroscopy to analyze chemically different materials. Half of these patients progressed to a metastatic form of the disease, while the other half had no evidence of it after treatment.

RMI was successful in distinguishing the chemical differences of patients who progressed to the metastatic state in comparison to those who had no sign of the cancer.

"The results we've experienced thus far with RMI are encouraging," said John Maier, Vice President of Biomedical Research at ChemImage. "We plan on continuing this research on prostate cancer, as we investigate the application of RMI to other cancers such as lung and kidney."

Complete results of this study will be published in the August 11 issue of the British Journal of Urology International, an internationally distributed peer-reviewed journal focused on urology, in an article titled "Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?".

For more information regarding ChemImage's work on prostate cancer, visit: http://www.chemimage.com/BJU.

If your organization would like to participate in future RMI research studies, contact John Maier at maier@chemimage.com.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

ChemImage to Present Findings at the International Conference on Raman Spectroscopy

Pittsburgh, PA -- (SBWIRE) -- 08/05/2010 -- Raman molecular imaging (RMI), a form of hyperspectral imaging, shows promise in identifying cancers that are typically difficult to diagnose. Its history, successes and current advancements will be discussed at the International Conference on Raman Spectroscopy (ICORS), Aug. 13 from 8:30 – 10:00 a.m. at the Boston Park Plaza Hotel in Boston.

Presented by Shona Stewart, Ph.D., senior scientist at ChemImage, "Advancing Raman Molecular Imaging for Disease Diagnosis" will discuss application of RMI in histopatholgy settings.

"As RMI is still an evolving technology, we're looking forward to sharing this important work with an international group of our peers and gaining some valuable feedback," said Dr. John Maier, Vice President of Biomedical Research at ChemImage.

RMI combines image information familiar to clinicians with spectral data in each pixel to imprint a digital molecular stain, unique to each sample, without the use of reagents. Images are acquired from tissue samples illuminated by a laser in a microscope and then analyzed by chemometric-based classification algorithms.

So far, RMI has shown great success in differentiating disease states in tissue, especially from the kidney and prostate. ChemImage continues to conduct and present RMI research on how it can:

- Discriminate between two challenging kidney disease diagnoses: oncocytoma, a benign condition and chromophobe renal cell carcinoma, a malignant one.
- Predict progression in prostate cancer, where slow-growing prostate cancer is difficult to differentiate from more aggressive forms.

For more information on RMI's role in pathology, visit http://www.chemimage.com/AP. If your organization would like to participate in future RMI research studies, contact John Maier at maier@chemimage.com.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 05/17/2010 -- ChemImage Corporation will be presenting and exhibiting at the 37th Annual Meeting and Exposition of the Controlled Release Society, an international gathering focused on the science and technologies behind the delivery of bioactive agents, July 10-14 at the Oregon Convention Center in Portland, Ore.

"We're really looking forward to participating in this year's meeting and sharing some relevant findings about Raman chemical imaging's (RCI) ability to help improve product performance of controlled release drug delivery systems," said Dr. Ryan Priore, Director of Applications and Contract Services at ChemImage.

These findings and more will be the focus of ChemImage's educational seminars at the four-day conference, including:

• Releasing Technologies Workshop: Using RCI to Characterize Controlled Release Systems
Presented by: Oksana Olkhovyk, Senior Scientist
Sunday, July 11, 10-11 a.m. PT
Wide-field RCI can be used to improve product performance by gaining a better understanding of the formulation design and manufacturing process. This workshop will examine the benefits of RCI and its success in evaluating controlled release and adhesive systems, polymorph identification and blend uniformity.

• Poster Presentation: RCI Characterization of Layered Homogeneity in Controlled Release Beads
Presented by: Oksana Olkhovyk, Senior Scientist
Wednesday, July 14, 12:30-1:30 p.m. PT
In this study, RCI coupled with optical microscopy was applied to investigate coating integrity and thickness in commercial controlled release (CR) beads used in a common generic antidepressant drug. Rich spectral and spatial information provided by this method is especially valuable for beads containing two or more distinct layers. Data and findings will be discussed.

For more information on ChemImage's activities at the Controlled Release Society Annual Meeting, visit http://www.chemimage.com/news/events/crs-2010.aspx.

About ChemImage
ChemImage Corporation, a leader in Hyperspectral Imaging technology (including Chemical and Molecular Imaging), provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations. The company's proprietary, state-of-the-art Hyperspectral Imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 05/03/2010 -- Recent research conducted by scientists at ChemImage Corporation revealed that wide-field Raman Chemical Imaging (RCI) shows promise as an in vitro method for identifying drug particle size distribution of Advair Discus® 500/50, a commercial dry powder inhaler with two active pharmaceutical ingredients.

A dry powder inhaler delivers medication directly to the lungs, so the understanding of its particle size distribution specific to each ingredient is important in determining its delivery rate, stability, dosage, efficacy and safety.

RCI is a technique used to obtain spectrally and spatially resolved images of a sample, allowing for accurate chemical identification and size measurements. This method, named ingredient-specific particle sizing, enabled easy identification of Advair's active pharmaceutical ingredients—fluticasone propionate and salmeterol xinafoate — based on the Raman spectral signature.

"The success this method had in clearly characterizing multiple ingredients in a DPI will allow for a better understanding of formulation efficacy," said Dr. Ryan Priore, Director of Applications and Contract Services at ChemImage. "Ultimately, this knowledge will lead to a safer, more effective and better quality drug product for consumers."

Oksana Olkhovyk, Senior Applications Scientist at ChemImage, will present further details on the study's findings at Particles 2010, an international conference examining the science, technology and business aspects of particle technology, May 22-25 at the Regal Sun Resort in Lake Buena Vista, Fla. This is the first time any information on wide-field RCI and its value in analyzing dry powdered inhalers will be shared.

In previous ChemImage studies, RCI was successfully used to analyze the ingredient-specific particle size of several corticosteroid aqueous suspensions including Rhinocort AQ™ and Flonase™ and metered-dose inhalers such as Combivent®.

For more information, visit http://www.chemimage.com/news/events/particles-2010.aspx or contact ChemImage at 1-877-241-3550.

About ChemImage
ChemImage Corporation, a leader in Chemical Imaging technology, provides instrumentation, software, contract services and expert consulting to government, industrial and academic organizations for numerous applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. The company's proprietary, state-of-the-art Chemical Imaging technology can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Pittsburgh, PA -- (SBWIRE) -- 04/07/2010 -- ChemImage Corporation announced today the receipt of its 100th U.S. patent, number 7,692,776 for a chemical imaging explosives optical sensor that detects explosive compounds.

Over the past 16 years, ChemImage has invested substantial resources in building a robust patent portfolio which includes patents for chemical imaging instrumentation, image analysis, threat detection, forensics tools, pharmaceutical analysis, particle sizing, and biomedical diagnostics.

"Issuance of our 100th patent represents a significant milestone in ChemImage's development," said Dr. Patrick Treado, ChemImage Founder and Chief Technology Officer. "As a technology company that is addressing critical measurement needs across a variety of industries, we have secured substantial protection of our intellectual property that will assist in fostering partnerships with market leaders worldwide."

ChemImage Corporation, a leader in Chemical Imaging technology, provides instrumentation, software and expert consulting to government, industrial and academic organizations for numerous applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. The company's proprietary, state-of-the-art Chemical Imaging technology can reveal critical chemical and biological information from a variety of material systems.

ChemImage's headquarters is located in Pittsburgh, Pennsylvania, where it houses research and development laboratories, as well as engineering and manufacturing facilities. For more information, contact ChemImage at +1 412-241-7335 or visit http://www.chemimage.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm